Pt | EGFR % | VEGFR % | MDR1% | TYMS % | DHFR % | ERCC1% | GST % | Protocol of targeted therapy | Response in association with intraarterial chemotherapy |
---|---|---|---|---|---|---|---|---|---|
1R | 45 | 70 | 80 | 0 | 0 | 0 | 18 | BEV | PR |
2R | 45 | 70 | 80 | 0 | 0 | 0 | 10 | BEV | PR |
3R | 50 | 65 | 65 | 0 | 0 | 0 | 10 | BEV | PR |
4R | 50 | 20 | 55 | 0 | 0 | 0 | 10 | CET | PR |
5R | 65 | 50 | 70 | 0 | 0 | 0 | 5 | CET | PR |
6R | 50 | 80 | 70 | 0 | 0 | 0 | 10 | BEV | PR |
7R | 50 | 20 | 80 | 10 | 0 | 25 | 20 | CET | PR |
8R | 50 | 20 | 60 | 0 | 0 | 0 | 10 | CET | PR |
9R | 50 | 30 | 65 | 10 | 0 | 0 | 10 | CET | PR |
10R | 70 | 60 | 70 | 0 | 0 | 0 | 0 | CET | PR |
11R | 60 | 55 | 65 | 5 | 0 | 0 | 10 | CET | PR |
12R | 60 | 55 | 65 | 5 | 0 | 0 | 15 | CET | PR |
13R | 40 | 70 | 80 | 5 | 10 | 0 | 10 | BEV | PR |
14R | 50 | 70 | 70 | 0 | 0 | 0 | 10 | BEV | PR |
15R | 50 | 20 | 65 | 0 | 0 | 0 | 15 | CET | PR |
16R | 65 | 70 | 80 | 0 | 0 | 0 | 18 | BEV | PR |
17R | 55 | 70 | 80 | 0 | 0 | 0 | 10 | BEV | PR |
18R | 60 | 85 | 70 | 0 | 0 | 0 | 10 | BEV | SD |
19R | 60 | 55 | 60 | 0 | 0 | 0 | 10 | CET | SD |
20R | 70 | 45 | 58 | 0 | 0 | 0 | 12 | CET | SD |
21R | 10 | 65 | 65 | 0 | 0 | 0 | 20 | BEV | SD |
22R | 50 | 80 | 70 | 0 | 0 | 0 | 10 | BEV | SD |
23R | 60 | 70 | 70 | 0 | 0 | 0 | 10 | BEV | SD |
24R | 80 | 35 | 60 | 0 | 25 | 0 | 0 | CET | SD |
25R | 60 | 70 | 70 | 0 | 0 | 0 | 0 | BEV | SD |
26R | 40 | 80 | 70 | 5 | 0 | 15 | 15 | BEV | SD |
27R | 40 | 60 | 60 | 0 | 0 | 0 | 10 | BEV | SD |
28 L | 50 | 70 | 70 | 10 | 0 | 0 | 10 | BEV | SD |
29 L | 40 | 50 | 60 | 0 | 10 | 0 | 10 | BEV | SD |
30 L | 60 | 85 | 70 | 0 | 0 | 0 | 10 | BEV | SD |
31*L | 65 | 80 | 83 | 0 | 0 | 0 | 10 | BEV | SD |
32 L | 50 | 80 | 60 | 0 | 0 | 0 | 8 | BEV | SD |
33 L | 60 | 90 | 70 | 0 | 0 | 0 | 10 | BEV | SD |
34 L | 60 | 30 | 70 | 0 | 0 | 0 | 10 | CET | SD |
35*L | 45 | 55 | 70 | 0 | 0 | 0 | 10 | BEV | SD |
36*L | 50 | 80 | 70 | 0 | 0 | 0 | 10 | BEV | PD |